So nothing is happening, it's easy to get frustrated and forget how compelling CRMD is. Two things happened recently that no one really noticed, but I think they are significant:
1) ND Partners recently allowed CRMD to delay a small milestone payment due upon issuance of the CE Mark in exchange for warrants with a strike of $1.50. The warrant strike was not in the PR but tucked away in the 8K and I think it's extremely bullish. Those warrants could have easily been at $0.50 or $1. I think the strike reflects to some degree ND Partner's expectation that this will be well north of $1.50 on CE Mark or shortly after.
2) Milby recently said in a press release "We anticipate compliance with the NYSE MKT listing standards from additional financing we will seek after the anticipated receipt of the CE Mark." NO financing prior to the Mark. This means they likely will be able to raise the cash they need to launch at higher prices and dilution will be minimal.
3) Guidance was Q1 until the packaging issue came up. This packaging issue likely caused at most a 3-4 week delay. In my opinion, we will hear from the regulators before the end of April.
4) Warrant volume has been very high the last 2 weeks with warrants selling for as high as $0.27. Someone is either very optimistic, knows something, or is very stupid.
Buy now in the $0.70s. My guess is you will double your money in less than 2 weeks.
I have been doing some research on CE and remain hopeful. It seems the CE is accepted in many locations outside of Europe once some additional paperwork requirement s have been met. Hopefully they can partner with one of the big 2 dialysis providers stateside(or both!) to aid with FDA registrational trial.
The other wildcard is the IP issue. At some point they will either settle with Tauropharm and get instant revenue or pursue their legal options in German court. In the most positive outcome, CRMD ends up as the monopoly provider of the product and then it must simply displace older (first generation---those that lack anti-microbia properties) products. Leverage here is significant since I think CRMD stays lean and mean for the first few years.